Literature DB >> 11698279

Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins.

I Bodó1, A Katsumi, E A Tuley, J C Eikenboom, Z Dong, J E Sadler.   

Abstract

Some families affected by von Willebrand disease type 1 show high penetrance with exceptionally low von Willebrand factor (VWF) levels. Previously, a mutation associated with this dominant phenotype, Cys1149Arg, was found to decrease the secretion of coexpressed normal VWF, and the mutation was proposed to cause intracellular retention of pro-VWF heterodimers. To demonstrate heterodimer formation, a model was developed in which subunits could be distinguished immunologically and by size. Recombinant VWF lacking domain A1 (dA1), A3 (dA3), or both (dA13) was secreted efficiently as a full range of multimers. Cotransfection of Cys1149Arg and dA13 resulted in the secretion of multimeric VWF containing about 250 kd (Cys1149Arg) and about 210 kd (dA13). Cell lysates contained pro-VWF forms of Cys1149Arg and dA13. Immunoprecipitation with an antidomain A1 antibody recovered both subunits in heterodimers, and subunit ratios were consistent with random dimerization. Similar results were obtained for cotransfection of Cys1149Arg and dA1. Normal VWF has a Cys1149-Cys1169 intrachain bond. When cotransfected with normal VWF, Cys1149Arg or the double mutant Cys1149Arg+Cys1169Ser caused a similar decrease in VWF secretion, suggesting that an unpaired Cys1169 does not explain the intracellular retention of Cys1149Arg. VWF Cys1149Arg was not secreted from BHK cells but was degraded intracellularly within about 4 hours, and the proteasome inhibitor lactacystin delayed its clearance more than 16 hours. Thus, dominant von Willebrand disease type 1 may be caused by heterodimerization of mutant and normal subunits in the endoplasmic reticulum followed by proteasomal degradation in the cytoplasm. A similar dominant negative mechanism could cause quantitative deficiencies of other multisubunit proteins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698279     DOI: 10.1182/blood.v98.10.2973

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

2.  The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF.

Authors:  Sandra L Haberichter; Ulrich Budde; Tobias Obser; Sonja Schneppenheim; Cornelia Wermes; Reinhard Schneppenheim
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

3.  A classification system for cross-reactive material-negative factor XI deficiency.

Authors:  Dmitri V Kravtsov; Paul E Monahan; David Gailani
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

4.  Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage.

Authors:  Paula M Jacobi; Joan Cox Gill; Veronica H Flood; David A Jakab; Kenneth D Friedman; Sandra L Haberichter
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

5.  Functional characterisation of the type 1 von Willebrand disease candidate VWF gene variants: p.M771I, p.L881R and p.P1413L.

Authors:  Ergul Berber; Mehmet Ozbil; Christine Brown; Zafer Baslar; S Hande Caglayan; David Lillicrap
Journal:  Blood Transfus       Date:  2016-07-25       Impact factor: 3.443

6.  Biogenesis of Weibel-Palade bodies in von Willebrand's disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation.

Authors:  Jiong-Wei Wang; Dafna J Groeneveld; Guy Cosemans; Richard J Dirven; Karine M Valentijn; Jan Voorberg; Pieter H Reitsma; Jeroen Eikenboom
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

Review 7.  Structure and function of factor XI.

Authors:  Jonas Emsley; Paul A McEwan; David Gailani
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

8.  Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

Authors:  Sandra L Haberichter; Giancarlo Castaman; Ulrich Budde; Ian Peake; Anne Goodeve; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; Stefan Lethagen; John Pasi; Frank G H Hill; Robert R Montgomery
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

9.  Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.

Authors:  Almudena Pérez-Rodríguez; Aranzazu García-Rivero; Esther Lourés; Maria Fernanda López-Fernández; Angela Rodríguez-Trillo; Javier Batlle
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

10.  Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi.

Authors:  Angie R Purvis; Julia Gross; Luke T Dang; Ren-Huai Huang; Milan Kapadia; R Reid Townsend; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.